Fingolimod (Gilenya®)

The National Health Care Institute has advised on amending the conditional inclusion of the medicine fingolimod (Gilenya®) in the Medicines Reimbursement System (GVS), whereby they reached the following conclusion.

Based on the criteria of the GVS, the National Health Care Institute completely removing the condition to fingolimod's inclusion in List 2 and replacing it with another condition.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.